Patient description: The patient is a 20 year old Caucasian female presents to the clinic with one-sided vision lost and facial weakness, dysarthria and numbness lasting for 1 day. She visited her PCP and underwent brain MRI which revealed a single plaque in the brainstem. After few months, she experienced lower extremities weakness led to balance problem. The second MRI revealed another lesion in the left cerebral hemisphere. The diagnosis of Relapsing Remitting Multiple Sclerosis (RRMS) is confirmed after the second MRI. Her past surgical history is significant for a C-section 2 years ago and she has a one child. She is divorced and is not currently in any sexual relationship. She smokes 10 cigarettes per day and drinks alcohol occasionally. She is working as an editor in a publisher company and she is happy that she can keep working from home most of the time. She is under the treatment of RRMS from 7 months ago.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Autoimmune Diseases Non-small Cell Lung Cancer Rheumatoid Arthritis Psoriasis Giant Cell Arteritis Polymyalgia Rheumatica Systemic Lupus Erythematosus Crohn Disease Multiple Sclerosis Ulcerative Colitis Age > 18 2. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 3. Metastatic, locally advanced or recurrent NSCLC, not amenable to curative therapy. 4. Patients should have received at least one platinum-based chemotherapy regimen for recurrent or metastatic disease or have received platinum-based chemotherapy as part of adjuvant or neoadjuvant therapy and experienced progression of disease within 6 months of completing therapy. 5. Patients with tumor genetic alterations such as EGFR, ALK, ROS1 or BRAF V600E alterations for which there is FDA-approved targeted therapy must have been treated with the appropriate targeted inhibitors in prior therapy 6. No limit on number of prior therapies 7. Ability to provide written, informed consent 8. Patients must be on a stable regimen of treatment for their autoimmune condition without need for addition of new medications or escalating doses of preexisting medications in the previous 12 weeks prior to study entry 9. In addition, patients with the following autoimmune diseases must have baseline disease activity scores as follows (please see Appendix A) For rheumatoid arthritis: DAS28 < 5.1 For polymyalgia rheumatica: PMR-AS < 17 For Sjogrens: < 14 For ulcerative colitis: SSCAI < 5 For Crohn's disease: CDAI < 450 For systemic lupus erythroderma: < 20 For multiple sclerosis: EDSS < 5.5 10. Adequate organ and marrow function as defined by absolute neutrophil count ≥ 1,500/mcL platelets ≥ 100,000/mcL  No chemotherapy or radiotherapy within two weeks of study entry. Prior targeted therapy is allowed as long as at least 5 half-lives have elapsed since last dose. 2. All adverse events (other than alopecia) from prior therapy must be resolved to Grade 1 or less. 3. Patients who are known to be HIV positive are excluded due to the known immunologic alterations associated with the disease. HIV testing is not required. 4. No uncontrolled intercurrent illness such as active infection, or psychiatric illness or social situation that in the judgment of the investigator would limit compliance with study requirements 5. No active interstitial lung disease (ILD) or pneumonitis, or a history of ILD or pneumonitis requiring treatment with corticosteroids 6. No live vaccine within 30 days of start of study treatment 7. No carcinomatous meningitis or untreated CNS metastases 8. No history of significant cardiac disease or presence of an abnormality in electrocardiograms that, in the investigator's opinion, is medically exclusionary or clinically meaningful 9. No other active malignancy 10. No known history of or positivity for active hepatitis B or C. HBV DNA and/or HCV RNA must be undetectable and HBsAg must be negative at the time of screening 11. No active unstable angina and/or congestive heart failure, or myocardial infarction within 6 months prior to protocol participation